Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study

Abstract EN

Objective.

To investigate the potential benefits of acarbose treatment on cardiovascular disease (CVD) in patients with type 2 diabetes by using nationwide insurance claim dataset.

Research Design and Methods.

Among 644,792 newly diagnosed type 2 diabetic patients without preexisting CVD in a nationwide cohort study, 109,139 (16.9%) who had received acarbose treatment were analyzed for CVD risk.

Those with CVD followed by acarbose therapy were also subjected to analysis.

Result.

During 7 years of follow-up, 5,081 patients (4.7%) developed CVD.

The crude hazard ratio (HR) and adjusted HR were 0.66 and 0.99, respectively.

The adjusted HR of CVD was 1.19, 0.70, and 0.38 when the duration of acarbose use was <12 months, 12–24 months, and >24 months, respectively.

Adjusted HR was 1.14, 0.64, and 0.41 with acarbose cumulative doses <54,750 mg, 54,751 to 109,500 mg, and >109,500 mg, respectively.

Conclusion.

In patients with type 2 diabetes without preexisting CVD, treatment with acarbose showed a transient increase in incidence of CVD in the initial 12 months followed by significant reductions of CVD in prolonged acarbose users.

After the first CVD events, continuous use of acarbose revealed neutral effect within the first 12 months.

The underlying mechanisms require further investigations.